Xeris Pharmaceuticals Inc (NASDAQ: XERS) saw its stock soar 9.81% in the pre-market session on Thursday, following the release of its outstanding fourth quarter and full-year 2024 financial results, along with robust revenue guidance for 2025.

The biopharmaceutical company reported record total revenue of $60.1 million for the fourth quarter, representing a substantial 35.4% increase year-over-year. This impressive growth was driven by strong sales of its key products, Gvoke and Recorlev. Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia, saw its net revenue rise 24.8% to $23.3 million, while Recorlev, a treatment for endogenous Cushing's syndrome, more than doubled its revenue to $22.6 million, reflecting a remarkable 130.6% increase.

The robust quarterly performance translated into a record full-year 2024 revenue of $203.1 million, up 23.9% compared to the prior year. Gvoke and Recorlev continued their momentum throughout the year, with revenue growth of 23.5% and 117.5%, respectively, reflecting the increasing demand for these innovative therapies.

Xeris also achieved positive cash flow and Adjusted EBITDA of $8.3 million in the fourth quarter, highlighting the company's improving financial position and operational efficiency. This strong financial performance has positioned Xeris for further growth and investment in its pipeline.

Looking ahead, the company provided an optimistic revenue guidance for 2025, projecting total revenue in the range of $255 million to $275 million. This represents a growth of over 30% at the mid-point of the range, fueled by the continued market share gains and expanding demand for Gvoke, Recorlev, and its other products. Investors have responded positively to this robust outlook, driving the stock's pre-market surge.